Drug Pipeline

Adebrelimab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
26
Active Studies
15
Recruiting
1
Phase 3
10
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-10 NCT07640048 Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study Recruiting
Active Studies by Phase
Phase 3
1
Phase 2
20
Phase 1/2
2
Not specified
3
Active Trials — top 25 of 26
NCT IDTitleConditionStatus
Phase 3
NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab… Advanced Hepatocellular Carcinoma Recruiting
Phase 2
NCT07309185 Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After… Stomach Neoplasms Recruiting
NCT07364305 HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC ICC Recruiting
NCT06610734 Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With… Small Cell Lung Cancer Extensive Stage Recruiting
NCT07437898 Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study Esophageal Squamous Cell Carcinoma Recruiting
NCT06885814 Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With… Esophageal Squamous Cell Carcinoma Recruiting
NCT07353684 Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric… Adebrelimab Recruiting
NCT07241793 Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in… Urothelial Carcinoma Recruiting
NCT07569679 Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for… Biliary Tract Cancer Recruiting
NCT05582499 Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study… Breast Neoplasm Recruiting
NCT06339619 Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and… Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Recruiting
NCT07317778 Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2… Breast Cancer Early Stage Breast Cancer (Stage 1-3) Not Yet Recruiting
NCT07327411 Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced… Advanced Refractory Solid Tumors Not Yet Recruiting
NCT07266025 Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch… Gastric Adenocarcinoma Not Yet Recruiting
NCT07398560 Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor… Small Cell Lung Cancer Not Yet Recruiting
NCT07466927 Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With… HER2-negative Breast Cancer Not Yet Recruiting
NCT07543783 Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial… Adebrelimab (SHR-1316) Not Yet Recruiting
NCT07554768 Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC Head and Neck Squamous Cell Carcinoma Not Yet Recruiting
NCT07561775 Adebrelimab Plus S-1 for Resected Cholangiocarcinoma Cholangiocarcinoma Not Yet Recruiting
NCT07583550 Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then… Lung Not Yet Recruiting
NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as… Biliary Tract Cancer Active, Not Recruiting
Phase 1/2
NCT07392541 Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary… Advanced Biliary Tract Carcinoma Recruiting
NCT06427239 Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of… Pancreatic Cancer Recruiting
Not specified
NCT07434518 A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With… Small Cell Lung Cancer (SCLC) Recruiting
NCT07640048 Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study Intrahepatic Cholangiocarcinoma (Icc) Recruiting
Sponsors Running Adebrelimab Trials
Disease Areas
Get alerts when Adebrelimab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free